Adel is a company founded in 2016 by Professor Seung-Yong Yoon from the Department of Neuroscience at Ulsan College of Medicine, Seoul Asan Hospital, to develop new drugs and diagnostic biomarkers for neurodegenerative diseases, including Alzheimer's disease. The company plans to allocate the recent investment funds to advance the Phase 1 clinical trial of ADEL-Y01, a tau antibody candidate for the treatment of Alzheimer's dementia, currently underway in the United States. In September last year, Adel received approval from the U.S. Food and Drug Administration (FDA) to conduct Phase 1a and 1b trials to assess the safety and tolerability in humans. ADEL-Y01 is the world’s first antibody candidate that specifically targets acetylated tau (tau-acK280), a disease-specific variant associated with dementia, without affecting normal tau. The company also plans to use the investment to further the preclinical research and development of its subsequent drug pipeline, including the APOE4 antibody (ADEL-Y04). Additionally, Adel is developing other drug candidates targeting various proteins and a platform technology for Target Protein Degradation.

ADTAC™ (Autophagic Degradation Targeting Chimera) : ADTAC is capable of degrading not only soluble proteins, but also highly misfolded proteins, large-sized aggregates, lipids, and pathogens. Additionally, ADTAC can degrade damaged organelles. Its activity is independent of both proteasome activity and E3-ligase.

Private

Biotech